

To obtain copies of the supporting statement and any related forms for the proposed paperwork collections referenced above, access HCFA's Web Site address at <http://www.hcfa.gov/regs/prdact95.htm>, or E-mail your request, including your address, phone number, OMB number, and HCFA document identifier, to [Paperwork@hcfa.gov](mailto:Paperwork@hcfa.gov), or call the Reports Clearance Office on (410) 786-1326. Written comments and recommendations for the proposed information collections must be mailed within 60 days of this notice directly to the HCFA Paperwork Clearance Officer designated at the following address:

HCFA, Office of Information Services, Security and Standards Group, Division of HCFA Enterprise Standards, Attention: Julie Brown, Room N2-14-26, 7500 Security Boulevard, Baltimore, Maryland 21244-1850.

Date: October 24, 2000.

**John P. Burke III,**

*HCFA Reports Clearance Officer, HCFA Office of Information Services, Security and Standards Group, Division of HCFA Enterprise Standards.*

[FR Doc. 00-28171 Filed 11-1-00; 8:45 am]

**BILLING CODE 4120-03-U**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Health Care Financing Administration

[Document Identifier: HCFA-R-0232]

#### Agency Information Collection Activities: Proposed Collection; Comment Request

**AGENCY:** Health Care Financing Administration, HHS.

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Health Care Financing Administration (HCFA), Department of Health and Human Services, is publishing the following summary of proposed collections for public comment. Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

*Type of Information Collection Request:* Extension; *Title of Information Collection:* Supporting Statement for Medicare Program Integrity Program Organizational Conflict of Interest Disclosure Certificate and Supporting Regulations in 42 CFR 421.310 and 421.312; *Form No.:* HCFA-R-0232 (OMB# 0938-0723); *Use:* This information is used to assess whether contractors who perform, or who seek to perform, Medicare Integrity Program functions, such as medical review, fraud review or cost audits, have organizational conflicts of interest and whether any conflicts have been resolved. The entities providing the information will be organizations that have been awarded, or seek award of, a Medicare Integrity Program contract; *Frequency:* On occasion; *Affected Public:* Businesses or other for profit; *Number of Respondents:* 10; *Total Annual Responses:* 10; *Total Annual Hours:* 2,400.

To obtain copies of the supporting statement and any related forms for the proposed paperwork collections referenced above, access HCFA's Web Site address at <http://www.hcfa.gov/regs/prdact95.htm>, or E-mail your request, including your address, phone number, OMB number, and HCFA document identifier, to [Paperwork@hcfa.gov](mailto:Paperwork@hcfa.gov), or call the Reports Clearance Office on (410) 786-1326. Written comments and recommendations for the proposed information collections must be mailed within 60 days of this notice directly to the HCFA Paperwork Clearance Officer designated at the following address: HCFA, Office of Information Services, Security and Standards Group, Division of HCFA Enterprise Standards, Attention: Julie Brown, Room N2-14-26, 7500 Security Boulevard, Baltimore, Maryland 21244-1850.

Dated: October 24, 2000.

**John P. Burke III,**

*HCFA Reports Clearance Officer, HCFA Office of Information Services, Security and Standards Group, Division of HCFA Enterprise Standards.*

[FR Doc. 00-28172 Filed 11-01-00; 8:45 am]

**BILLING CODE 4120-03-U**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Health Resources and Services Administration

#### National Vaccine Injury Compensation Program; List of Petitions Received

**AGENCY:** Health Resources and Services Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Health Resources and Services Administration (HRSA) is publishing this notice of petitions received under the National Vaccine Injury Compensation Program ("the Program"), as required by section 2112(b)(2) of the Public Health Service (PHS) Act, as amended. While the Secretary of Health and Human Services is named as the respondent in all proceedings brought by the filing of petitions for compensation under the Program, the United States Court of Federal Claims is charged by statute with responsibility for considering and acting upon the petitions.

**FOR FURTHER INFORMATION CONTACT:** For information about requirements for filing petitions, and the Program in general, contact the Clerk, United States Court of Federal Claims, 717 Madison Place, N.W., Washington, D.C. 20005, (202) 219-9657. For information on HRSA's role in the Program, contact the Director, National Vaccine Injury Compensation Program, 5600 Fishers Lane, Room 8A-46, Rockville, MD 20857; (301) 443-6593.

**SUPPLEMENTARY INFORMATION:** The Program provides a system of no-fault compensation for certain individuals who have been injured by specified childhood vaccines. Subtitle 2 of title XXI of the PHS Act, 42 U.S.C. 300aa-10 *et seq.*, provides that those seeking compensation are to file a petition with the U.S. Court of Federal Claims and to serve a copy of the petition on the Secretary of Health and Human Services, who is named as the respondent in each proceeding. The Secretary has delegated her responsibility under the Program to HRSA. The Court is directed by statute to appoint special masters who take evidence, conduct hearings as appropriate, and make initial decisions as to eligibility for, and amount of, compensation.

A petition may be filed with respect to injuries, disabilities, illnesses, conditions, and deaths resulting from vaccines described in the Vaccine Injury Table (the Table) set forth at section 2114 of the PHS Act or as set forth at 42 CFR 100.3, as applicable. This Table lists for each covered childhood vaccine the conditions which will lead to compensation and, for each condition, the time period for occurrence of the first symptom or manifestation of onset or of significant aggravation after vaccine administration. Compensation may also be awarded for conditions not listed in the Table and for conditions that are manifested after the time periods specified in the Table, but only

if the petitioner shows that the condition was caused by one of the listed vaccines.

Section 2112(b)(2) of the PHS Act, 42 U.S.C. 300aa-12(b)(2), requires that the Secretary publish in the **Federal Register** a notice of each petition filed. Set forth below is a list of petitions received by HRSA on April 3, 2000, through June 30, 2000.

Section 2112(b)(2) also provides that the special master "shall afford all interested persons an opportunity to submit relevant, written information" relating to the following:

1. The existence of evidence "that there is not a preponderance of the evidence that the illness, disability, injury, condition, or death described in the petition is due to factors unrelated to the administration of the vaccine described in the petition," and

2. Any allegation in a petition that the petitioner either:

(a) "Sustained, or had significantly aggravated, any illness, disability, injury, or condition not set forth in the Table but which was caused by" one of the vaccines referred to in the Table, or

(b) "Sustained, or had significantly aggravated, any illness, disability, injury, or condition set forth in the Table the first symptom or manifestation of the onset or significant aggravation of which did not occur within the time period set forth in the Table but which was caused by a vaccine" referred to in the Table.

This notice will also serve as the special master's invitation to all interested persons to submit written information relevant to the issues described above in the case of the petitions listed below. Any person choosing to do so should file an original and three (3) copies of the information with the Clerk of the U.S. Court of Federal Claims at the address listed above (under the heading "For Further Information Contact"), with a copy to HRSA addressed to Associate Administrator, Bureau of Health Professions, 5600 Fishers Lane, Room 8-05, Rockville, MD 20857. The Court's caption (Petitioner's Name v. Secretary of Health and Human Services) and the docket number assigned to the petition should be used as the caption for the written submission.

Chapter 35 of title 44, United States Code, related to paperwork reduction, does not apply to information required for purposes of carrying out the Program.

#### List of Petitions

1. Tammy Sharp on behalf of Daniel Sharp, Houston, Texas, Court of Federal Claims Number 00-0176V
2. Catherine M. Wucker, Vienna, Virginia, Court of Federal Claims Number 00-0179V
3. Maureen E. Carr, Vienna, Virginia, Court of Federal Claims Number 00-0180V
4. Jennifer K. Duncan, Vienna, Virginia, Court of Federal Claims Number 00-0181V
5. Jill S. Whetmore-Brown and Michael Brown on behalf of Michael Brown, Flower Mound, Texas, Court of Federal Claims Number 00-0182V
6. Christy and Wesley Duncan on behalf of Jacob Wesley Duncan, Temple, Texas, Court of Federal Claims Number 00-0183V
7. Ellen and Allen Dye on behalf of Mark Allen Dye, Jr., Berkley Springs, West Virginia, Court of Federal Claims Number 00-0184V
8. Patricia and Ira Bonner on behalf of Jenna Nicole Bonner, Bluffton, South Carolina, Court of Federal Claims Number 00-0194V
9. Suzanne Chouinard on behalf of Julien Chouinard, Boston, Massachusetts, Court of Federal Claims Number 00-0196V
10. Margo Ferro on behalf of Nico Ferro, Scarsdale, New York, Court of Federal Claims Number 00-0201V
11. Annamma Abraham, Dallas, Texas, Court of Federal Claims Number 00-0203V
12. Andrea J. Newman, Houlton, Maine, Court of Federal Claims Number 00-0206V
13. Isabel Salgado, Chicago, Illinois, Court of Federal Claims Number 00-0219V
14. Jacqueline Chait, Portland, Maine, Court of Federal Claims Number 00-0224V
15. Helen Harwell on behalf of Mari Hall, Deceased, Dallas, Texas, Court of Federal Claims Number 00-0230V
16. Charron Sayre on behalf of Gabriel Sayre, Fairborne, Ohio, Court of Federal Claims Number 00-0231V
17. Nancy Whittington, Lafayette, Louisiana, Court of Federal Claims Number 00-0232V
18. Anthony Wright, Amarillo, Texas, Court of Federal Claims Number 00-0233V
19. Norma Jean Steele on behalf of Tiffany Jane Steele, Pensacola, Florida, Court of Federal Claims Number 00-0235V
20. Ruth and Walter Quiller on behalf of Timothy Quiller, Augusta, Georgia, Court of Federal Claims Number 00-0252V
21. Marcy and Michael Tarrants on behalf of Blake Tarrants, Sedalia, Missouri, Court of Federal Claims Number 00-0256V
22. Arthur Beaty on behalf of Sheronda Beaty, Rochester, New York, Court of Federal Claims Number 00-0266V
23. Elaine Pietrucha on behalf of Bradley Pietrucha, Milford, New Jersey, Court of Federal Claims Number 00-0269V
24. Debra Keith Elizabethtown, Kentucky, Court of Federal Claims Number 00-0273V
25. Rhonda Rogers on behalf of Nathan D. Rogers, Lottsburg, Virginia, Court of Federal Claims Number 00-0276V
26. Kristen and Patrick Strain on behalf of Zachary P. Strain, Waterville, New York, Court of Federal Claims Number 00-0279V
27. Gina and Carl Geppert on behalf of Carl Lee Geppert, III, Vienna, Virginia, Court of Federal Claims Number 00-0286V
28. Patricia Groht, Vienna, Virginia, Court of Federal Claims Number 00-0287V
29. Jill and Dugan Dietz on behalf of Lukas Jackson Dietz, Deceased, Wheeling, West Virginia, Court of Federal Claims Number 00-0288V
30. Melynda Slay on behalf of Harrison Bryce Slay, Aurora, Colorado, Court of Federal Claims Number 00-0289V
31. Amanda Fussell on behalf of Samantha Butts, Deceased, Palm, California, Court of Federal Claims Number 00-0309V
32. Jill F. Thigpen, Vienna, Virginia, Court of Federal Claims Number 00-0319V
33. Firas and Rania Sallaj on behalf of Zena Sallaj, Buffalo, New York, Court of Federal Claims Number 00-0321V
34. Kathy and Todd Meena on behalf of Cameron Todd Meena, Orlando, Florida, Court of Federal Claims Number 00-0327V
35. Juan Perez and Irma Hernandez on behalf of Daphne Perez, Los Angeles, California, Court of Federal Claims Number 00-0328V
36. Linda Cook on behalf of Michael Cook, Vienna, Virginia, Court of Federal Claims Number 00-0331V
37. Esther Maupins, Lexington, Kentucky, Court of Federal Claims Number 00-0332V
38. Joe Jacobs on behalf of Chanz Jacobs, Bay City, Michigan, Court of Federal Claims Number 00-0333V
39. Nancy Hilliard on behalf of Owen S. Hilliard, Ramona, California, Court of Federal Claims Number 00-0341V
40. Laurie Ann Amimoto on behalf of Jacqueline Amimoto, Sacramento, California, Court of Federal Claims Number 00-0342V

41. Kyle Youngberg Ames, Iowa, Court of Federal Claims Number 00-0345V
42. Wanda E. Dennis on behalf of Brian Keith Wingate, Manning, South Carolina, Court of Federal Claims Number 00-0346V
43. Tracy and Scott Weeks on behalf of Jenica Weeks, Deceased, Boston, Massachusetts, Court of Federal Claims Number 00-0348V
44. Chue Xiong, Sacramento, California, Court of Federal Claims Number 00-350V
45. Marion Underwood on behalf of Cesar Zachary Moreno, Deceased, Boston, Massachusetts, Court of Federal Claims Number 00-0357V
46. Ann Haynes on behalf of Elizabeth Haynes, Boston, Massachusetts, Court of Federal Claims Number 00-0358V
47. Cynthia Wells on behalf of Ezra James McCorkle, Boone, North Carolina, Court of Federal Claims Number 00-0359V
48. Sandra and William Spoon on behalf of William Spoon, Phoenix, Arizona, Court of Federal Claims Number 00-0360V
49. Kimberly Willingham on behalf of Courtney Willingham, Rockford, Illinois, Court of Federal Claims Number 00-0363V
50. Kristin and Mark Rogers on behalf of Colin Rogers, Chapel Hill, North Carolina, Court of Federal Claims Number 00-0368V
51. Stephanie and Cory Geho on behalf of Griffin Cole Geho, Portsmouth, Ohio, Court of Federal Claims Number 00-0370V
52. Sherri Lynn Boothby, Vienna, Virginia, Court of Federal Claims Number 00-0371V
53. Kristin Rogers on behalf of Colin Rogers, Chapel Hill, North Carolina, Court of Federal Claims Number 00-0372V
54. Anthony Joseph Tedesco, Clinton Township, Michigan, Court of Federal Claims Number 00-0373V

Dated: October 26, 2000.

**Claude Earl Fox,**

*Administrator.*

[FR Doc. 00-28136 Filed 11-1-00; 8:45 am]

**BILLING CODE 4160-15-U**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### **National Cancer Institute: Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Identification and Development of Chemical Compounds That Interact With the Polo-Box of Polo Kinases, as Potential Therapeutic Targets for the Inhibition of Cellular Proliferation**

**AGENCY:** National Institutes of Health, PHS, DHHS

**ACTION:** Notice.

**SUMMARY:** Members of the polo subfamily of protein kinases play important roles in cell proliferation, and regulation of polo kinases may be crucial in the control of cell division. The polo kinases contain a distinct region of homology in the C-terminal non-catalytic domain, termed the polo-box. Scientists from the National Cancer Institute (NCI) have demonstrated that over-expression of this non-catalytic C-terminal domain in budding yeast results in a dominant-negative inhibition of cell division. NCI seeks a Cooperative Research and Development Agreement (CRADA) Collaborator to aid in the identification and development of chemical compounds that interact with the polo-box of polo kinases, as potential therapeutic targets for the inhibition of cellular proliferation.

**DATES:** Interested parties should notify this office in writing of their interest in filing a formal proposal no later than January 2, 2000. Potential CRADA Collaborators will then have an additional thirty (30) days to submit a formal proposal. CRADA proposals submitted thereafter may be considered if a suitable CRADA Collaborator has not been selected.

**ADDRESSES:** Inquires and proposals regarding this opportunity should be addressed to Laurie W. Whitney, Ph.D., Technology Development Specialist (Tel: 301-496-0477, FAX: 301-402-2117), Technology Development and Commercialization Branch, National Cancer Institute, 6120 Executive Blvd., Suite 450, Rockville, MD 20852. Inquiries directed to obtaining patent license(s) needed for participation in the CRADA opportunity should be addressed to Vasant Gandhi, J.D., Ph.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Blvd., Suite 325, Rockville, MD 20852, (Tel: 301-496-7056, ext. 224, FAX: 301-402-0220).

**SUPPLEMENTARY INFORMATION:** A Cooperative Research and Development Agreement (CRADA) is the anticipated joint agreement to be entered into with NCI pursuant to the Federal Technology Transfer Act of 1986 and Executive Order 12591 of April 10, 1987 as amended by the National Technology Transfer Advancement Act of 1995. NCI is looking for a CRADA partner to aid NCI in the identification and development of chemical compounds which act as polo-box inhibitors. The expected duration of the CRADA would be from one (1) to five (5) years.

Members of the polo subfamily of protein kinases appear to play pivotal roles in cell division and proliferation. These include mammalian Plk, Snk, and Fnk/Prk, *Xenopus laevis* Plx1, *Drosophila melanogaster* polo, *Schizosaccharomyces pombe* Plo1, and *Saccharomyces cerevisiae* Cdc5. The polo subfamily members are characterized by the presence of a distinct region of homology in the C-terminal non-catalytic domain, termed the polo-box, which is essential for subcellular localization and mitotic functions of the polo kinases. Regulation of polo kinases may be crucial in the control of cell division. In mammalian cells, Plk is expressed at high levels in mitotically active cells and in tumors of various origins. Constitutive expression of Plk in NIH3T3 cells induces oncogenic focus formation, and these Plk-transformed cells can form tumors in nude mice. These data suggest that Plk expression is closely related to cellular proliferation, and that uncontrolled Plk expression may lead to the development of cancers in humans. Genetic and biochemical analyses indicate that polo kinases regulate diverse cellular events at various stages of the M phase. In addition to their roles in spindle formation and centrosome maturation, polo kinases appear to regulate important biochemical steps at the G2/M transition, such as activation of Cdc2 through Cdc25C phosphatase, DNA damage checkpoint adaptation, and activation of the anaphase-promoting complex (APC) in various eukaryotic systems. In addition, recent data suggest that polo kinases play important roles in cytokinesis.

In budding yeast, overexpression of the non-catalytic C-terminal domain of either Plk or Cdc5 (plk $\Delta$ N or cdc5 $\Delta$ N), but not the corresponding polo-box mutant, results in severe connected cell morphology. Provision of functional Cdc5 remedies this phenotype, indicating that over-expression of cdc5 $\Delta$ N or plk $\Delta$ N results in a dominant-negative inhibition of cell division and